tirzepatide mash fda Approves Semaglutide for F.D.A. Approves New Obesity Drug

OFA also submitted a comment to the FDA that argues the semaglutide shortage remains ongoing: OFA conservatively estimates that roughly 80 million prescriptions for semaglutide were fulfilled with compounded semaglutide in the last 12 months, inclusive of 503A pharmacy compounders and 503B outsourcing facilities

It is often discussed in the context of learning, memory, and brain plasticity

n = 48/group

Clinical Evidence: Real Weight Loss Results from GLP-1 Therapy Randomized controlled trials demonstrate that semaglutide-treated patients lose 10-15% of their body weight over 68 weeks, compared to 2-3% with lifestyle changes alone